Spending like a bigger company on purpose: current results carry the cost of an expansion aimed at demand management say
The model's full reasoning — Q3 2017 call → NOWe need to determine if the transcript shows both halves: (1) expansion already underway and visibly costing something now, and (2) justification based on demand already real. Let's analyze the transcript. Management discusses various things. They mention investments in software development, capitalized software investments, product development. They also mention new products like Nurse Residency Pathway, OB Risk program, Knowledge Q. They mention signing new strategic partners for resuscitation products. They mention moving phone operations to Nashville, which was completed in Q2. They mention increased bad debt expense, but that's not expansion cost. They mention ASC 606 compliance costs. Do they describe an expansion that is costing them now? They talk about increased capitalized software development, which is an investment. But do they say it's weighing on current profitability? They mention that operating expenses were up 2% but they had leverage. They mention that they are investing in product development. However, they don't explicitly say that this expansion is depressing current results. They do mention that they have increased guidance on capital expenditures to reflect increased software development activity. But they don't say it's hurting margins. They also talk about new products that are just starting to show revenue. They mention that they are in development mode for new technologies. They mention signing new partners for resuscitation products that will launch in 2019. But that's future. Do they justify with demand already real? They mention that one of their largest customers selected their OB Risk program, and also renewed early for five years. They mention that all six new products have shown revenue and sales orders. They mention that they have seen recovery in sales orders in Q3. But is that demand already real? Yes, they have orders and contracts. But the question is: does management acknowledge that current results are being visibly weighed down by the cost of an expansion already undertaken? They don't seem to say that. They talk about investments but not that they are weighing down results. They actually had a good quarter with revenue up 9%, operating income up 210%. So they are not complaining about costs.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| LMAT | LeMaitre Vascular, Inc. | Q3 2021 | 2021-10-29 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| JBT | John Bean Technologies Corporation | Q2 2018 | 2018-07-26 | B |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
SIBN · Q3 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken — spending, hirin...YES Management explicitly describes the expansion as already underway and costing the company now: investments in sales force (85 territory managers + 72 specialists), new products (iFuse-TORQ, iFuse-Bedrock Granite), instrument trays, inventory, and R&D that are driving higher depreciation, freight, and product costs 84% gross margin (down low-single digits from these factors). Anshul confirms “we’ve made a substantial amount of investment whether it’s in TORQ trays or Granite trays or TORQ implants” and “this is going to lead to elevated depreciation,” while Laura notes the build supports “strong new product demand.
FLYW · Q1 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken, AND justify carr...YES The transcript shows management explicitly linking the current EBITDA decline to the hiring expansion already completed ("increased the number of FlyMates by over 50% during the past year" and "added over 100 new FlyMates within the sales, marketing and product functions"), while framing the spending as a deliberate, ongoing 2022 investment plan that is already delivering observable results through record client adds (130), pipeline growth, and strong ARR signings.
EVGO · Q2 2022 → YESThe question is: Does management acknowledge that the company's CURRENT reported results are being visibly weighed down by the cost of an expansion the company has ALREADY undertaken, AND justify carr...YES Management describes concrete expansion already underway—170 stalls placed in Q2, total stalls at 2,397 with 460 under construction, pipeline at 3,669, CapEx jumped to $44 million to accelerate deployment, and G&A ramping personnel to support growth—while directly tying the resulting negative adjusted EBITDA of -$19.8 million to that deliberate build-out.